xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

362

KUANetal.

TABLE XXXII.3 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Kotoet al. 2146

1. The 5-year likelihood of grade 2 + RIBI and grade 2 + clinical symptoms were 25% and 7%, respectively 2. Brain volume receiving > 50Gy was a risk factor for development of grade 2 + RIBI 3. RIBI most frequently developed in the ipsilateral temporal lobe 1. 21% of patients experienced acute grade 3 toxicities, most commonly mucositis and dermatitis 2. 6% of patients experienced late grade 3 toxicities, most commonly vision loss 3. 49% of patients experienced late grade 1–2 toxicities, most commonly epiphora and brain necrosis 1. Four patients underwent ICA occlusion due to active bleeding or at-risk ICA 2. Five patients underwent endoscopic endonasal debridement with 1. The most common grade 3 + acute AEs were dermatitis, mucositis, pain, and dysphagia 2. From baseline, the following PROMs worsened: acute–subacute XeQoLS physical functioning, pain, personal/psychological distress, and social functioning; acute–subacute MDADI physical function; and acute–subacute FACT-HN subscale 3. No PROMs were worse in the chronic period ( > 90days) compared to baseline. (Continues) temporoparietal fascial flap coverage of exposed bone 3. One patient received pentoxifylline, tocopherol, and clodronate 4. Survival at a mean of 24 months was 57%

RIBI as assessed byMRI and clinical

2014 3

Prospective cohort

39 patients with skull base tumors treated with carbon ion RT

symptoms of brain injury

Fanet al. 442

2021

4

Retrospective case series

86 patients with

Treatment toxicities

paranasal sinus tumors receiving intensity-modulated proton therapy

Daoudi et al. 2163

1. Management of sphenoid ORN 2. Survival rate at follow-up

2020 4

Retrospective case series

Seven patients with sphenoid ORN

treated with medical management, endovascular treatment, and/or surgery

Pasalic et al. 522

2020 4

Retrospective case series

64 patients with SNM treated with proton beam therapy

PROMs and toxicity as

measured by theCTCAE, XeQoLS, MDASI, and FACT scales